Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04485702
Recruitment Status : Completed
First Posted : July 24, 2020
Last Update Posted : February 23, 2021
Sponsor:
Collaborator:
Worldwide Clinical Trials
Information provided by (Responsible Party):
Melt Pharmaceuticals

Tracking Information
First Submitted Date  ICMJE July 17, 2020
First Posted Date  ICMJE July 24, 2020
Last Update Posted Date February 23, 2021
Actual Study Start Date  ICMJE July 20, 2020
Actual Primary Completion Date August 29, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 23, 2020)
  • Peak Plasma Concentration (Cmax) [ Time Frame: 24 hours ]
  • Area under the plasma concentration versus time curve (AUC) [ Time Frame: 24 hours ]
  • Time to peak plasma concentration (Tmax) [ Time Frame: 24 hours ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine
Official Title  ICMJE A Pilot Phase 1, Randomized, Single-Dose, 6-Sequences, 3-Period, Crossover Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual Tablet) and Intravenous Midazolam or Ketamine in Healthy Volunteers
Brief Summary Comparative Bioavailability study testing MELT-100 (midazolam and ketamine sublingual tablet) and IV midazolam or ketamine in healthy volunteers
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
Randomized, Single-Dose, 6-Sequence, 3-Period, Crossover
Masking: Single (Participant)
Masking Description:
randomization
Primary Purpose: Other
Condition  ICMJE Healthy Volunteers
Intervention  ICMJE
  • Drug: Midazolam injection
    2mg IV
  • Drug: Ketamine Injectable Product
    6mg IV
  • Drug: MELT-100
    midazolam 3mg and ketamine 25mg SL tablet
Study Arms  ICMJE
  • Active Comparator: MELT-100
    3mg midazolam and 25mg ketamine sublingual tablet
    Intervention: Drug: MELT-100
  • Active Comparator: IV midazolam
    2mg Intravenous midazolam
    Intervention: Drug: Midazolam injection
  • Active Comparator: IV ketamine
    6mg Intravenous ketamine
    Intervention: Drug: Ketamine Injectable Product
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 22, 2021)
17
Original Estimated Enrollment  ICMJE
 (submitted: July 23, 2020)
18
Actual Study Completion Date  ICMJE August 29, 2020
Actual Primary Completion Date August 29, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • A subject must satisfy all of the following criteria to be eligible for study participation:

    1. Able to understand and voluntarily consent to participation in this study, and provides written informed consent before the start of any study-specific procedures.
    2. Healthy adult male or female ≥55 years of age.
    3. Normally active and otherwise judged to be in good health on the basis of medical history and physical examination.
    4. Has vital signs (measured sitting after a minimum 3 minutes rest) at Screening within the following ranges: heart rate: 40-100 bpm; systolic blood pressure (BP): 90-145 mmHg; diastolic BP: 50-95 mmHg. Out-of-range vital signs may be repeated once.
    5. Has a body temperature ≤37.7 degrees C
    6. Body weight ≥55 kg
    7. Body mass index (BMI) 18.0 to 32.0 kg/m2 (inclusive)
    8. Female subjects are eligible only if the following applies:

      Surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy), or postmenopausal (confirmed with serum FSH at Screening)

    9. Male subjects must either be surgically sterile (vasectomy at least 3 months prior to first dose) or agree to use an acceptable method of birth control (see Section 4.4) from Screening through EOS.
    10. Is willing and able to remain in the study unit for the entire duration of each confinement period.

Exclusion Criteria:

  • Subjects will be excluded from study participation for any of the following:

    1. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, ophthalmologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
    2. Has a history of glaucoma, asthma, chronic obstructive pulmonary disease, or thyroid disease.
    3. Clinically significant illnesses within 4 weeks of the administration of study medication (including flu, flu-like symptoms, diarrhea, vomiting, fever, sore throat) or acute illness at the time of either the pre-study medical evaluation or dosing.
    4. Has been in contact with someone within the last month who has tested positive for SARS-CoV-2.
    5. Clinically significant surgery within 4 weeks prior to the administration of the study medication.
    6. Has participated in another clinical trial (randomized subjects only) within 30 days before the first dose of study medication.
    7. An active malignancy of any type, or has been diagnosed with cancer within 5 years prior to Screening (excluding squamous or basal cell carcinoma of the skin).
    8. History or presence of allergic or adverse response to midazolam, ketamine, Versed, KETALAR, or any ingredients of MELT-100 or related drugs.
    9. Use of any over-the-counter (OTC) medication (including nutritional or dietary supplements, herbal preparations, or vitamins) within 7 days before the first dose of study medication until the EOS without evaluation and approval by the Investigator.
    10. Use of any prescription medication, except statin drugs or hormonal replacement therapy, from 14 days before the first dose of study medication until the EOS without evaluation and approval by the Investigator.
    11. Have had a depot injection or an implant of any drugs 3 months prior to administration of study medication.
    12. Has been treated with any known drugs that are moderate or strong inhibitors/inducers of cytochrome P450 (CYP) enzymes (e.g., barbiturates, phenothiazines, cimetidine, carbamazepine) within 30 days before the first dose of study medication, and that, in the Investigator's judgment, may impact subject safety or the validity of the study results.

      Specifically, the use of any drugs known to inhibit CYP2C9 and CYP3A4 enzymes (examples include amiodarone, fluconazole, ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit or orange or apple juice) or any drugs that are highly protein-bound (for example, warfarin, cyclosporine, amphotericin B) within 30 days prior to the first dose of study medication, and that in the Investigator's judgment may impact subject safety or the validity of the study results.

    13. Blood or plasma donation within 30 days before the first dose of study medication until the EOS. It is recommended that blood/plasma donations not be made for at least 30 days after the EOS.
    14. Has any prior history of substance abuse or treatment (including alcohol).

      1. History of significant alcohol abuse within 6 months of Screening or any indication of the regular use of more than 2 units of alcohol per day (1 unit = 50 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).
      2. History of use of marijuana within 3 months of Screening or drugs such as cocaine, phencyclidine (PCP), within 1 year of Screening.
    15. Smoking or use of tobacco- or nicotine-containing products within 60 days before the first dose of study medication until the EOS Note: Nonsmokers are preferred for this study.
    16. Any food allergy, intolerance, restriction, or special diet that, in the opinion of the Investigator, contraindicates the subject's participation in this study.
    17. Has been on a significantly abnormal diet during the 4 weeks preceding the first dose of study medication.
    18. Consumption of beverages or foods that contain alcohol, grapefruit, poppy seeds, broccoli, Brussels sprouts, pomegranate, star fruit, char-grilled meat, or caffeine/xanthine from 48 hours before the first dose of study medication until the EOS. Subjects will be instructed not to consume any of the above products; however, allowance for an isolated single incidental consumption may be evaluated and approved by the study Investigator based on the potential for interaction with the study drug.
    19. Engagement in strenuous exercise from 48 hours before the first dose of study medication until the EOS.
    20. A clinically significant abnormal finding on the physical examination, medical history, electrocardiogram (ECG), or clinical laboratory results at Screening.

      Note: Laboratory test values above or below the normal range does not necessarily indicate that the value is "clinically significant." The determination should be made at the discretion of the Investigator with consultation, when necessary, with the Sponsor.

    21. Presence of active infection, mucositis, cold sores, apthous ulcers, vesicles, viral lesions, local irritation/inflammation, or periodontal disease of the oral cavity. In addition, evidence of piercings of the tongue or anywhere in the oral cavity, history of oral cavity piercings, or history of significant dental disease or braces or oral hardware.
    22. Clinically significant ECG abnormalities at Screening.
    23. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ˃1.25 times the upper limit of normal at Screening or Check-in for Period 1.
    24. Is a female with a positive pregnancy test result.
    25. Has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates) or cotinine.
    26. Has a positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) at Screening or has been previously treated for hepatitis B, hepatitis C, or HIV infection.
    27. Has poor venous access during blood sampling at Screening.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 55 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04485702
Other Study ID Numbers  ICMJE MELT-100-001
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Melt Pharmaceuticals
Study Sponsor  ICMJE Melt Pharmaceuticals
Collaborators  ICMJE Worldwide Clinical Trials
Investigators  ICMJE
Principal Investigator: Cynthia Zamora, MD Worldwide Clinical Trials
PRS Account Melt Pharmaceuticals
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP